24-26 April 2018

San Francisco, USA

Download Event Guide



Post-Conference Workshop Day

Tuesday April 24, 9:00 am-12:00 pm


Understanding Innate Resistance to Anti-PD-1 Therapy in
Melanoma Through Transcriptomics

09:00 am -12:00 pm  Workshop Leader

Immunotherapy consisting of blocking immune
checkpoints, such as PD-1, has shown promise in
treating melanoma. However, innate and acquired
resistance to anti-PD-1 therapy often results in
recurrence after initial successful treatment leading to advanced Metastatic melanoma.

This workshop will include in-depth coverage of the bioinformatics solutions from QIAGEN used to analyze and interpret whole transcriptome and targeted RNA sequencing results from pretreatment mRNAs of patients with advanced metastatic melanoma and with respect to their subsequent immunotherapy treatment outcomes. We will show how to optimize the transcriptome data and will provide highlights into the biological signatures that determine non-responder versus responder status using Ingenuity Pathway Analysis (IPA).

jean Noel Billaud

Dr. Jean-Noel Billaurd, Senior Principal Scientist, QIAGEN


Dr. Samuel Rulli, Global Product Manager, QIAGEN